Our laboratory focuses on cell fate determination, organogenesis, how those are affected by human genetic mutations, and leveraging that knowledge for regenerative medicine.
We investigate the molecular events regulating developmental decisions that instruct cardiac progenitor cells to adopt a cardiac cell fate and subsequently fashion a functioning heart. We focus on integration of gene networks involving signaling, transcriptional and post-transcriptional steps.
We've leveraged this knowledge to reprogram fibroblasts directly into cardiomyocyte-like cells for regenerative purposes. We also investigate the causes of human cardiovascular disease by applying modern genetic technologies for the study of complex traits such as congenital heart disease. By using human induced pluripotent stem cells, CRISPR approaches, and mouse genetics, we're developing a deep understanding of the biology underlying cardiogenesis and cardiovascular disorders. This knowledge is leading to new therapeutic approaches for heart disease.
Deepak Srivastava, MD
Deepak Srivastava is president of Gladstone Institutes. He is also the Robert and Linda Mahley Distinguished Professor and a senior investigator at the Gladstone Institute of Cardiovascular Disease, and director of the Roddenberry Stem Cell Center. At UC San Francisco, Srivastava is a professor in the Departments of Pediatrics (Division of Cardiology) and Biochemistry and Biophysics, and is the Wilma and Adeline Pirag Distinguished Professor in pediatric developmental cardiology.
A Change of Heart: Heart Development from Embryo to Adult
In these videos, Deepak Srivastava describes how a better understanding of the molecular pathways driving embryonic heart development may help to develop new therapeutics for both congenital and adult heart disease.
Lab Members
